Overview
NICE is unable to make a recommendation on dasatinib (Sprycel) for Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults because Bristol Myers Squibb did not provide an evidence submission.
Last reviewed: 14 July 2021
Next review: We will review this decision if the company decides to make a submission.